OKYO Pharma Ltd banner
O

OKYO Pharma Ltd
LSE:OKYO

Watchlist Manager
OKYO Pharma Ltd
LSE:OKYO
Watchlist
Price: 1.4 GBX -24.32% Market Closed
Market Cap: £23.2m

OKYO Pharma Ltd
Investor Relations

OKYO Pharma Ltd operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The GPCRs is the family of membrane proteins involved in many biological processes. GPCRs is used for the treatment of various conditions, including cardiovascular disease, cancer, and diabetes. Its product pipeline includes OK-101 for Dry Eye Disease (DED), OK-101 for Non-ophthalmic Indications, and OK-201 to treat corneal neuropathic pain. The OK-101 is its lead preclinical product candidate, which is focused on keratoconjunctivitis sicca commonly known as DED which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The OK-201 is a non-opioid analgesic for ocular pain management without side effects and the potential abuse associated with opioid medications.

Show more
Loading
OKYO
FTSE All Share Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Gary S. Jacob Ph.D.
CEO & Exec. Director
No Bio Available
Mr. Michael Paul Beck
Founder
No Bio Available
Ms. Keeren Shah
Chief Financial Officer
No Bio Available
Dr. Rajkumar Patil Ph.D.
Chief Scientific Officer
No Bio Available

Contacts

Address
London
55 Park Lane
Contacts
+442074952379.0
okyopharma.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett